middle.news
Can Anteris Turn $42.7M Loss Into DurAVR Trial Success?
8:49am on Tuesday 12th of August, 2025 AEST
•
Healthcare
Read Story
Can Anteris Turn $42.7M Loss Into DurAVR Trial Success?
8:49am on Tuesday 12th of August, 2025 AEST
Key Points
Net loss widened 22% to $42.7 million in H1 2025
Revenues declined 16% to $1.17 million due to contract expirations
Raised $80 million net from December 2024 IPO
Scaled manufacturing and qualified 79 clinical trial sites for PARADIGM Trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AVR
OPEN ARTICLE